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Summary A mathematical model was developed to improve understanding of the biodistribution and
microscopic profiles of drugs and prodrugs in a system using enzyme-conjugated antibodies as part of a two-
step method for cancer treatment. The use of monoclonal antibodies alone may lead to heterogeneous uptake
within tumour tissue; the use of a second, low molecular weight agent may provide greater penetration into
tumour tissue. This mathematical model was used to describe concentration profiles surrounding individual
blood vessels within a tumour. From these profiles the area under the curve and specificity ratios were
determined. By integrating these results spatially, average tissue concentrations were determined and compared
with experimental results from three different systems in the literature: two using murine antibodies and one
using humanised fusion proteins. The maximum enzyme conversion rate (Vmax) and the residual antibody
concentration in the plasma and normal tissue were seen to be key determinants of drug concentration and
drug-prodrug ratios in the tumour and other organs. Thus, longer time delays between the two injections,
clearing the antibody from the bloodstream and the use of 'weaker' enzymes (lower Vmax) will be important
factors in improving this prodrug approach. Of these, the model found the effective clearance of antibody
outside of the tumour to be the most effective. The use of enzyme-conjugated antibodies may offer the
following advantages over the bifunctional antibody-hapten system: (i) more uniform distribution of the active
agent; (ii) higher concentrations possible for the active agent; and (iii) greater specificity (therapeutic index).
Keywords: enzyme-conjugated antibody; mathematical model; prodrug; two-step therapy
At present monoclonal antibodies have not realised their
potential to treat solid tumours in patients (Sands, 1992).
Frequently, antibodies are not delivered uniformly or in
adequate quantities in tumours (Jain, 1994). On the other
hand, traditional chemotherapeutic agents or radionuclides
penetrate more rapidly throughout the tumour, but their
toxic effects are not limited to cancer cells. For this reason
two-step approaches to cancer therapy are being developed
that seek to combine the specificity of monoclonal antibodies
with the greater penetration and faster clearance of small
molecules (e.g. Paganelli et al., 1991; Yuan et al., 1991).
The use ofenzyme-conjugated antibodies (ECAs; Figure 1)
in combination with prodrugs is one promising two-step
approach (Bagshawe et al., 1988; Senter et al., 1988, 1992).
An antibody or antibody fragment that binds to a tumour-
associated antigen is conjugated to an enzyme not present in
the host and injected into the bloodstream. The ECA will
penetrate tissues throughout the body, and after a few days
or a week should be localised primarily within the tumour
owing to high-affinity binding (albeit non-uniformly distrib-
uted; Yuan et al., 1991). At this time a prodrug, which is a
non-toxic precursor of a cytotoxic agent, is injected into the
body. The role of the enzyme is to convert the prodrug back
to the toxic form of the drug. Ideally, this will occur only
where the enzyme is present, which is primarily in the
tumour. The drug is then free to penetrate throughout the
tumour, and the concentration levels in the blood and in
normal tissues are minimised.
Previous studies by our group and others have shown the
presence of a binding site barrier for high-affinity antibodies,
which may prevent penetration of macromolecules in some
regions of a tumour, on both macroscopic and microscopic
length scales (Baxter and Jain, 1989, 1990, 1991a,b; Fujimori
et al., 1989, 1990; Sung et al., 1992; van Osdol et al., 1991;
Weinstein and van Osdol, 1992). The ECA-prodrug system is
similar in some ways to the use of bifunctional antibodies (Le
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Doussal et al., 1990; Stickney et al., 1989, 1991), for which
we have also determined the microscopic distribution profiles
(Baxter et al., 1992). A specific application of the bifunctional
antibody (BFA) system involving the high-affinity biotin-
streptavidin system (Hnatowich et al., 1987; Paganelli et al.,
1991) has also been recently modeled (Sung et al., 1994; van
Osdol et al., 1993). The BFA binds to a low molecular weight
agent (referred to as a hapten in this manuscript), which may
be cytotoxic itself, or radiolabelled. The three main
differences between the use of bifunctional vs ECAs are: (i)
the prodrug and drug molecules do not bind to the antibody
or the tumour-associated antigen (other than to react), and so
are not trapped in the tumour by any specific binding; (ii) a
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Figure 1 Schematic of the enzyme-conjugated antibody-
prodrug approach. A prodrug is converted to a more toxic form
by an enzyme which has been linked to a monoclonal antibody
that targets an antigen associated with the tumour tissue.Microscopic model for ECA-prodrug therapy
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single ECA molecule may convert a large number of prodrug
molecules, whereas a BFA molecule may at one time bind to
only one or possibly a small number of hapten molecules in
addition to the tumour-associated antigen and; (iii) a
radiolabelled hapten is ideally suited for cancer detection
and/or killing distant cells, whereas such applications may be
difficult within the ECA framework. It was expected that
concentration profiles would be more uniform in the ECA
system; but conversely, rapid prodrug conversion just outside
of the blood vessel could lead to non-uniform drug profiles,
depending on the relative contribution of diffusion, reaction
and permeability. There are a number of physiological and
kinetic parameters that may influence uptake and distribution
of the prodrug and drug. We therefore wanted to test the
relative importance ofthese transport factors, discern optimal
choices for parameters that are under the control of the
clinician or experimentalist and compare model simulations
with available results from the literature.
There have been many experimental studies using ECA and
prodrugs. Bagshawe and co-workers (Bagshawe, 1987;
Bagshawe et al., 1988) have conjugated the enzyme carbox-
ypeptidase and used a prodrug that is an aromatic nitrogen
mustard linked to a glutamyl moiety. Senter et al. (1988) used
an alkaline phosphatase enzyme and the prodrug etoposide
phosphate (converted to etoposide). They found complete
tumour regression in 40% of the animals whereas the
administration of etoposide alone was ineffective. They used
the same enzyme with mitomycin phosphate (Sahin et al., 1990;
Senter, 1989) and phenol mustard phosphate (Wallace and
Senter, 1991). Haisma et al. (1992) used an antibody-fi
glucuronidase conjugate to activate epirubicin -glucuronide in
an in vitro system. Wang et al. (1992) also used an antibody-fl-
glucuronidase conjugate with a glucuronide prodrug, which is
over 150 times less toxic than the parent drug. Penicillin V ami-
dase (Bignami et al., 1992; Kerr et al., 1990; Vrudhula et al.,
1993) and fl-lactamase (Shepherd et al., 1991; Svensson et al.,
1992) systems, as well as prodrugs based on traditional anti-
cancer agents have also beendeveloped. It is desirable to have a
high differential between activity in the tumour and reactions in
the rest of the body. fl-lactamase enzymes have excellent
potential owing to their favourable kinetics and broad
substrate specificities, and their absence in mammalian species
(Svensson et al., 1992). Another potential advantage is their
ability to becompetitively inhibited. Svensson etal. (1992) used
a cephalosporin mustard, which is at least 50 times less
cytotoxic than its toxic form, phenylenediamine mustard.
For all the work done in this area of antibody-directed
enzyme-prodrug therapy, comparatively little is known on
the biodistribution of the various components. Smith and
Thijssen (1986) have developed a preliminary mathematical
(compartmental) model for the distribution of drugs
following local activation. The first and most comprehensive
experimental study on the biodistribution of active drugs
after site-specific activation of prodrugs is by Antoniw et al.
(1990). They present data on the concentration of prodrug
and drug, and enzyme activity, in nude mice bearing human
CC3 choriocarcinoma xenografts, for plasma, tumour, liver,
kidney and lung. Their system was A5B7F(ab')2 antibody
fragment conjugated to carboxypeptidase G2, which converts
a derivative of benzoic acid mustard to its active form. As the
importance of in vivo transport issues has been acknowl-
edged, more studies measuring the local concentrations of
ECA and/or prodrug and drug have been published. Bosslet
et al. (1992) developed a fusion protein for prodrug
activation consisting of a humanised anti-CEA region and
human /3-glucuronidase using recombinant DNA technology
and have measured the plasma pharmacokinetics and average
concentrations in the liver, lung, kidney, intestine, heart and
several tumour lines in nude mice (Bosslet et al., 1994). In
their in vivo study, a long time delay of 7 days between
protein and prodrug injection was used to increase specificity
as suggested in Yuan et al. (1991). Wallace et al. (1994)
carried out studies in nude mice to determine the in vivo
conversion of a 5-fluorouracil (5-FU) prodrug 5-fluorocyto-
sine (5-FC), measuring the antibody (L6), prodrug and drug
concentrations in the plasma, liver, kidney, lung, spleen,
muscle, and in H2981 (L6-binding) and H3719 (L6-non-
binding) tumours. In the present study we have compared
our model simulations when possible with these diverse sets
of experimental data, which include sufficient biodistribution
data (Antoniw et al., 1990; Bosslet et al., 1994; Wallace et
al., 1994). A key aim of developing this model was to
provide a basis for the optimisation of ECA-prodrug
therapy. The ability of models to provide novel insight for
this approch is evidenced by this quote from Hellstr6m and
Senter (1991)
'Yet another variable concerns the kinetics of drug release
by the targeted enzyme. It would be of interest to test the
validity of recent pharmacokinetic model studies suggesting
that low turnover rates may result in higher tumour to blood
drug ratios if the conjugate concentration in the tumour is
higher than in the blood (Yuan et al., 1991). These same
analyses also suggest that under some conditions there may
be advantages in enzymes with high Km values.'
We hope that the present model furthers understanding of
the ECA approach.
Materials and methods
Model development
The tissue is modelled as a Krogh cylinder (Krogh, 1922), in
which a microvessel of radius p is surrounded by tissue of
radius L. Diffusion reaction equations are written to describe
the extravascular concentrations as a function of both time
and radial position. These differential equations (in both
tissue and plasma) were solved simultaneously using a
numerical finite difference method. The antibody-antigen
binding is assumed to be specific, linear and saturable, and
the prodrug conversion is assumed to follow Michaelis-
Menten kinetics.
There are four extravascular species undergoing unsteady-
state diffusion and/or reaction:
6- DAV CA - kfCAAg + krCB
6Cp- DPV2CO VmaxCAOPkSC
-t=_ --2Cp +A knsCP Et KM+ CP
6CD DVC VmaxCACP -DD D+ +knsCP 6t Km±+CP
6t
(1)
(2)
(3)
(4) kfCAAg - krCB- k CB
where V2 is the Laplacian operator
V2 13 ( 6C\ VC equals-- r- r6r 6r
in cylindrical coordinates, D is the effective diffusion
coefficient, t is the time after injection, r is the distance
from the centre of the blood vessel (which has a radius of p),
CA is the free antibody concentration, CB is the bound
antibody concentration, Cp is the prodrug concentration, CD
is the drug concentration and Ag is the number of free
binding sites on the tumour cells (Ag =Ag°-CB). Metabolism
(antigen internalisation) is treated as a first-order process (ke),
that eliminates BFA bound to the tumour-associated antigen;
Vmax and KM are the Michaelis-Menten rate constants
characterising the prodrug conversion reaction in the
presence of the ECA enzyme; kf and kr are the association
and dissociation reaction rate constants for the binding of the
ECA to the TAA; and kns is the rate constant for non-specific
conversion of prodrug to drug.Microscopic model for ECA-prodrug therapy
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There is a no-flux boundary condition for mobile species
at the surface of the cylinder (r=L) owing to symmetry with
surrounding identical Krogh cylinders:
6ri Ir=L= 0 (i = A, P,D) (5)
The boundary condition at the blood vessel wall relates
the solute flux to the concentration gradient between the
plasma (Cil1) and interstitial concentrations and the
permeability (Pi) and partition (y,) coefficients (where yi is
the ratio of the interstitial to plasma concentrations at
equilibrium):
-Di Ir=p Pi(Ci1-Ci jr=p /^yi) (i = A, P,D) (6)
Equations must also be developed for the plasma
concentrations. Following Baxter et al. (1992) we use a
three-compartment model with saturable elimination to
describe the pharmacokinetics of the low molecular weight
agents and a two-compartment model for ECA, allowing for
conversion of prodrug to drug in all compartments where
enzyme is present:
dCil {Kl,i(Cil VmaxCAl CP1 K=ji-( ii- C11)} _i_
dtj=2 KM + Cpl
Kj0,iC1j (i = A, P, D) (7)
dt Ci =_ KjVai(Cij-Cilx _-i K CAj CP_
dt ~ Km + CP1
(i
= A, P, D;j
= 2,3) (8)
where OA =0, /, = and 4D = - 1, j represents the three
compartments, with Kjk,i representing the transfer coefficient of
species i from compartmentj to k and K,0 is the rate constant
for elimination from the plasma (e.g. via urine). These
compartmental transfer coefficients may be obtained from
the coefficients of the following expression that provides the
best fit to experimental data for the plasma concentration (Cil)
of free species (Gibaldi and Perrier, 1982). For the antibody, a
biexponential fit was sufficient to describe the plasma
pharmacokinetics. Without further physiological information
on ECA distribution, and with the smaller prodrug able to
move between the shallow and deep compartments, it was
assumed that there was no ECA in the deep compartment, and
hence no prodrug conversion. (Additional simulations without
this assumption resulted in no significant change in drug
concentration in the tumour or plasma.)
0Cii a1 exp-Alt ±+ A2 exp-A2t
+ (l a2)
ii It=0 exp-A3t (i = A, P, D) (9)
The initial conditions are zero concentrations in the
plasma and tissues for all species, with a step change in the
plasma antibody concentration at t =0+ to Cp° =dose/plasma
volume. Similarly when the prodrug is introduced there is a
step change at t = T from 0 to its initial plasma
concentration.
In the model we have not attempted to incorporate
pharmacodynamic effects, cellular internalisation or metabo-
lism. These effects, while important, vary tremendously from
one prodrug/drug system to another (e.g. depending upon
hydrophilicity, membrane transport, charge, mode of action
etc.) The model equations could be modified to incorporate
these effects for a specific drug but the equations above are
meant to be general for a system in which the concentration
at the site of action is proportional to the interstitial
concentration. If, for example, the drug were taken up in
an irreversible fashion by the cells, equation 3 would
represent the interstitial drug concentration, with an extra
term, -kintern xCDint, and another equation for the cellular
drug concentration:
= +kinterm CD-int X CD-cell
6t
Model parameters and simulations
The actual parameters used in the model depend upon the
exact enzyme, antibody, prodrug, tumour line etc. Since a
main purpose of this study is to compare the microscopic
distribution of ECA, drug and prodrug with the distribution
in other approaches such as bifunctional antibodies and
haptens, we have chosen the baseline model parameters to be
as close as possible to those used previously in Baxter et al.
(1992) and Yuan et al. (1991 for enzyme kinetic parameters).
These baseline parameters are summarised in Table I, and
represent a prodrug with a molecular weight of 600 and an
ECA or protein with characteristics similar to an F(ab')2
molecule. Further details on the source of these parameters
may be found in Baxter et al. (1992) and Yuan et al. (1991).
The simulations were based on a bolus injection of ECA 72 h
before prodrug administration. The equations given above
were solved numerically using the IMSL subroutine
DMOLCH, which uses the method of lines with cubic
hermite polynomials to solve a system of ordinary differential
equations obtained from a centered finite difference approx-
imation of the partial differential equations for diffusion
(IMSL, 1987).
In order to determine the effects of relevant physiological
parameters on the uptake and distribution of ECA and drug
we have carried out additional simulations varying each of
the important parameters. To allow comparison of different
conditions, each profile is analysed to calculate the average
concentration (<C>), area under the concentration -time
curve (AUC) for plasma and tumour. Since the ECA-prodrug
system may be beneficial only for therapy and not detection,
the instantaneous tumour-plasma level (specificity ratio) is
not as important as the relative total exposure to the drug,
i.e. the therapeutic index (TI=AUCtumour/AUCp1asma). As in
Baxter et al. (1992) we have calculated an index of spatial
uniformity (UNI), which is equal to the volume around the
blood vessel in which one-half of the ECA or drug has
distributed, divided by the equivalent volume under a
uniform distribution. Thus UNI, a function of time,
approaches zero when all the material is just outside of the
blood vessel and approaches unity for a uniform interstitial
distribution. The role of cellular uptake or elimination of
antibody may vary greatly from system to system. To study
the effect of antigen internalisation and/or antibody
metabolism on the resulting drug distribution in the ECA
system we have included a simulation with ke = 1.9 day-l (as
used in Baxter and Jain, 1991a; Baxter et al., 1992).
Results
Baseline simulations
Figure 2 shows the model simulations for the baseline
parameters for the prodrug and drug distribution in which
the prodrug is injected 3 days after ECA administration. The
spatial distribution is plotted for a series of time points. Note
that both the prodrug and drug concentration profiles are
quite uniform even at early time points. This is in contrast
with the profiles in Figure 3, which show the ECA
concentration as well as the hapten concentration following
BFA administration with the model from (Baxter et al.,
1992). In this figure, the antibody concentrations are
essentially constant over the short time that the drug is
present. The hapten molecules are mostly bound to the
antibody (for low hapten doses, and after the rapid clearance
phase for higher doses). Thus the perivascular hapten
distribution tends to mimic the antibody distribution. It is
also seen that the prodrug and drug molecules clear from the
body much more rapidly as they do not bind to the ECA (as
in the BFA-hapten approach). The main reason for the very
uniform profiles is that the conversion rate >> diffusion rate
>> permeability rate for molecules of this size in the
r9
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presence of a specific enzyme. Figure 4 shows the plasma and
tumour concentrations for both drug and prodrug as a
function of time. The drug levels are highest in the tumour,
where the conversion rates are greatest; hence the prodrug
levels in the tumour are less than in the plasma. It can be
seen that significant (and detrimental) conversion occurs
outside of the tumour for the baseline parameters.
Sensitivity analysis
Other simulations were carried out to determine the effect of
various parameters on the drug biodistribution: changes in
permeability, diffusivity, binding affinity, kinetic rate con-
stants and the time delay between ECA and prodrug
injections. The effect of clearing all antibody from outside
the tumour (via plasmapheresis or a chasing antibody) was
also studied. The concentration profiles for the prodrug and
drug were analysed as described above to yield information
on the tumour to plasma concentration ratios (T/P), average
concentrations <C>, therapeutic index (TI) and perivascu-
lar uniformity index (UNI). The results are given in Table II
in three sections. First the effect of doses and other clinical
parameters was studied. The clearing of ECA from tumour
and normal tissues before prodrug administration increased
the TI greatly, with only a small decrease in <C>.
Decreasing the initial dose of ECA was found to increase
the TI by reducing prodrug conversion in the plasma.
Similarly, waiting 7 days instead of 3 days between ECA
and prodrug injections resulted in a much higher TI. Altering
the dose of prodrug or drug had marginal effects on the TI,
with roughly proportional changes in the <C>. An
antibody of higher affinity (or with greater antigen
expression in the tumour) led to greater ECA concentrations
in the tumour and somewhat higher TI. When IgG was used
instead of F(ab')2 as the ECA, the TI dropped. This was
owing to an increase in the plasma ECA concentration (6.0 x
10-9M vs 2.5 x 10-9M after 3 days). Next, the enzyme
properties were studied. Using enzymes with a lower Vmax
resulted in a better TI, again by minimising conversion of
prodrug in the plasma and locations with low antibody
concentrations. As less drug would be produced, a greater
prodrug dose would be needed to compensate. Clearly, for a
very low Vmax insufficient drug will be produced and the
treatment will not be effective. Given a maximum allowable
prodrug concentration or AUC and a minimum effective
drug concentration or AUC, the model can be used to predict
an optimum Vmax for the enzyme. Finally, physiological
parameters were varied to see which might increase the TI.
Somewhat surprisingly, decreasing the prodrug and drug
permeabilities in the tumour led to a greater TI. This is owing
to the longer retention (slower escape) of the drug in the
tumour tissue. It is not clear whether lower permeabilities
would be more effective in practice, since one cannot always
make changes that affect just a single parameter. For
example, a drug with a lower permeability would often
have a longer plasma clearance half-life. Moderate metabo-
lism (degradation) of the ECA had little effect for a time
delay of 3 days but would further reduce the ECA
concentration at later times.
These simulations show that the parameters with the
greatest effect on the therapeutic index are the Vmax enzyme
rate constant, the time interval before prodrug injection and
the reduction in the plasma ECA concentration. All of these
parameters are reflections of the requirement to minimise
prodrug conversion outside of the tumour, rather than obtain
the highest possible conversion or concentration within the
tumour. Parameters that affect the therapeutic index to a
lesser degree are ECA molecular weight, binding affinity and
antibody dose (Table II). Along these lines, Eccles et al.
(1994) found sustained dose-dependent tumour stasis or
regression by waiting 12-14 days between injection of an
IgG2-carboxypeptidase ECA and a benzoyl-glutamic acid
prodrug in nude mice bearing c-erbB-2 breast carcinoma
xenografts.
Discussion
Comparison of model with experiments
Since there are no data available on the perivascular
distribution of prodrug and drug following ECA administra-
tion, we sought to compare the average concentrations
predicted by the model with whole tumour measurements in
the literature. There are three sets of published data from
Table I Baseline model parameters
D (cm2 s-1) Diffusion coefficient
P (cm s-1) Permeability coefficient
Partition coefficent
Initial plasma concentration
Pharmacokinetic parameters for free species:
Cl = ca exp(-21 t) + a2 exp(-A2t)+
(1 - a2)exp(-A3t)
Blood vessel radius
Intercapillary half-distance
Association rate constant
Dissociation rate constant
Binding affinity
Metabolism/internalisation rate constant
Antigen density
Maximum enzyme conversion rate (velocity)
Michaelis constant
Time delay between ECA and prodrug injections
ECA
2.0 x 10-8 Gerlowski and
Jain (1986)
9.0 x 10 Gerlowski and
Jain (1986)
1.0
2.0 x 10-8 Le Doussal
et al. (1990)
0.76 Stickney et al.
(1991)
0.24
4.44 x 10-' (ZCE-025/
CHA-255)
4.10x 10-
10
100
4.33 x 104
2.07 x 10-5
2.1 x 109
0 (2.17x 10 5)a
1.6x 10-7
6000
l.Ox 104
72
Prodrug, drug
4.3 x 10- Nugent and Jain
(1984)
1.0x 10 Jain (1987)b
1.0 -
1.0x 10 Yuan et al.
(1991)
0.69 Houston et al.
(1979)
0.24
0.588 ([113In]
3 10-2 DTPA)
3.34x1-
5.20x 10-3
Baxter and Jain (1991b);
Gerlowski and Jain (1986)
Baxter and Jain (1991b);
Gerlowski and Jain (1986)
Baxter and Jain (199la)
=kf!Ka
Le Doussal et al. (1990)
See text
Le Doussal et al. (1990)b
Senter (1989);
Yuan et al. (1991)
Nielsen and Bundgaard (1988);
Yuan et al. (1991)
Yuan et al. (1991)
y
C,° (M)
aC2
Ai (min-1)
A2 (mim ')
)3 (min-')
p (gm)
L (,um)
kf (M-1 S-1)
kr (s 1)
Ka (M )
ke (s 1)
Ag° (M)
Vmax (min 1)
KM (M)
T (h)
aBaseline value is zero, but the simulation which includes metabolism uses a value of 2.17 x 10-5 S-1 (Baxter and Jain, 1991a).
bAs determined indirectly in Baxter et al. (1992).Microscopic model for ECA-prodrug therapy
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Figure 2 Baseline parameter simulations. Prodrug (a); drug
extravascular concentrations in the tumour (b). Theoretical
concentrations are given at different times for prodrug injected
3 days after i.v. administration of ECA. Quite uniform
concentrations are seen, even at early times after prodrug
administration. Model parameters are given in Table I.
different groups that contain sufficient information (data and
parameters) to compare with our model (Antoniw et al.,
1990; Bosslet et al., 1994; Wallace et al., 1994). These three
studies look at different ECA and prodrug systems in nude
mice. All have taken some measures to address the problem
of non-specific conversion of prodrug outside the tumour.
Antoniw et al. (1990) and Bosslet et al. (1994) use long time
intervals before prodrug administration (6 and 7 days
respectively), whereas Wallace et al. (1994) use an anti-
idiotypic antibody to clear the ECA from the bloodstream.
Bosslet et al. (1994) also used an enzyme with a relatively low
Vmax. In the simulations described below, baseline parameters
were used unless different parameters were given in the
experimental study.
Carboxypeptidase G2-benzoic acid mustard Antoniw et al.
(1990) were the first to present the pharmacokinetics of ECA,
prodrug and drug together. They used carboxypeptidase G2
conjugated to F(ab')2-anti-human chorionic gonadotropin
antibody W14A to convert the prodrug 4-(bis (2-chloroethyl)
amino) benzoyl-L-glutamic acid to its activated derivative,
benzoic acid mustard. The prodrug was administered
(41 ,umol kg-' i.p.) to mice bearing human CC3 choriocarci-
r(gm)
Figure 3 (a) The ECA concentration is shown for the same time
scales as in Figure 2. (b) The concentration of hapten
(bound+ free) from Baxter et al. (1992) is shown for comparison
with the ECA approach. The relevant time scales are much longer
for the BFA-hapten system.
noma xenografts (0.5 -1.0 g in size) 6 days after i.v. injection
of 1000 U kg-' ECA. The baseline parameters were used
with the following changes in the enzyme kinetics and small
molecule plasma pharmacokinetics: Vmax=0.62x 106 limol
U- min-'; KM=4.5 pM (Springer et al., 1991); prodrug
ao=0.9716, X2=0.0162, A1=0.5min-', A2=0.0334min-',
A3=0.0052 min-; drug o1=0.9716, o2=0.0162, Al,=
0.5 min-', A2=0.0334 min-', )33=0.0052 min-' (fitted from
pharmacokinetic data). Vmax was converted to units of min-'
by assuming an initial enzyme plasma concentration of
2.0 x 10-8. (This choice is arbitrary but has no effect on the
results as long as the dose is below that needed to saturate
the tumour-associated antigen.) The model simulation for
these parameters is compared with the data in Figure 5, for a
drug partition coefficient of 0.17 [data values with standard
errors from Antoniw et al. (1990), kindly provided by Dr C
Springer]. The partition coefficient was estimated by fitting
the model to the data; this value reflects at least four
physiological or physicochemical factors. First, at equilibrium
the drug concentrations in the vascular and extravascular
spaces need not be the same; the ratio of the interstitial to
plasma equilibrium concentration is defined as the partition
coefficient, yi. Second, the uptake of prodrug may well be
a
8E-06 -
6E-06 -
-i
c
0
,, 4E-06-
C
a, a)
C
0
C-
2E-06 -
0
L
2.5E-05 -
2.OE-05 -
-i
C 1.5E-05-
4,
C-
70 )O
a
c.
C
C
c-
)
1.0E-05-
5.OE-06 -
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-
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n-
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flow limited in the tumour, i.e. the uptake may be affected average of vascular, intersitial and cellular fractions. Hence,
not by the permeability but by the regional blood flow rates the estimated yi is not necessarily the same as the true
(Yuan et al., 1993). Third, the tumour may have necrotic or equilibrium partition coefficient.
poorly perfused regions that have little or no blood supply
and hence reduced availability of prodrug. Fourth, the extent
to which the prodrug and drug are internalised by cells will
have an effect on the measured concentration, which is an
Time (min)
Figure 4 Plasma concentrations of prodrug and drug are plotted
as a function of time, 3 days after injection of ECA. The same
baseline parameters were used (Table I) as in previous figures.
0 100 200 300 400 500 600 700
Time (min)
Figure 5 Comparison with CG2-BA system of Antoniw et al.
(1990). The theoretical plasma (dotted line) and tumour
extravascular (dashed line) concentrations were calculated using
Ydrug:= 0.17 (see text for other parameters). The experimental drug
tissue concentrations in mice bearing human CC3 choriocarcino-
ma xenografts for plasma (m) and tumour (0) are given up to
12h after prodrug administration.
Table II Analytical indices from simulationsa
TIP <C> (105 M) UNI AUCb (10-5 MMin) Tlb
Prodrug Drug Prodrug Drug Prodrug Drug Prodrug Drug Prodrug Drug
A Doses
Baseline 0.138 1.23 0.0035 1.79 0.994 1.00 4.36 205 0.12 1.14
CP A 100 1.16 2.34 1.64 0.157 1.00 1.00 182 28.3 0.92 1.54
CP px 10 0.162 1.27 0.129 17.9 0.994 1.00 94.4 2000 0.17 1.24
COp 10 0.136 1.23 0.0003 0.18 0.994 1.00 0.38 20.6 0.12 1.12
CPOAX 10 and Cp0px 10 0.0136 1.22 0.0003 18.0 0.88 1.00 2.41 2090 0.012 1.06
Kax 10 0.14 1.60 0.055 1.74 0.998 1.00 9.12 200 0.12 1.41
IgG (instead of Fab'2)c 0.067 1.22 0.0006 1.80 0.988 1.00 1.65 208 0.068 1.08
1 week between ECA and prodrug 0.128 11.6 0.17 1.63 0.994 1.00 22.1 187 0.12 5.3
Clear ECA outside tumour 0.137 cc 0.202 1.60 0.993 1.00 28.2 181 0.13 00
A Enzyme properties
VmaxX 100
KM.+ 100
Baseline
Vmax 100, KM+ 100
Vm 100
Vmax. 10 000
A Physiological parameters
Baseline
Dp and DD X 100
Dp and DD-. 100
Pp and PD X 100
Pp and PD 100
Ag0x 10
Metabolism (ke = 1.87 day-')
Comparison with experimental result.
Baseline
0.0009 0.45 1.4e-8 1.79 0.37 1.00 0.0014 213 0.009 0.94
0.0009 1.22 l.9e-7 1.79 0.37 1.00 0.021 210 0.0012 1.06
0.138 1.23 0.0035 1.79 0.994 1.00 4.36 205 0.12 1.14
0.83 2.43 0.93 0.87 1.00 1.00 62.2 148 0.56 1.41
1.16 2.34 1.64 0.157 1.00 1.00 182 28.3 0.92 1.54
1.21 2.40 1.80 0.0016 1.00 1.00 210 0.32 0.97 1.55
0.138 1.23 0.0035 1.79 0.994 1.00 4.36 205 0.12 1.14
0.138 1.23 0.0035 1.79 0.994 1.00 4.36 205 0.12 1.14
0.032 0.86 0.0008 1.25 0.385 0.992 1.10 196 0.030 1.09
0.750 1.02 0.0190 1.48 0.994 1.00 28.2 187 0.78 1.04
0.016 0.51 0.0004 0.75 0.994 1.00 0.50 219 0.014 1.22
0.139 1.60 0.0550 1.74 0.999 1.00 9.05 200 0.122 1.41
1.21 1.22 0.48 1.32 1.00 1.00 50.9 159 0.69 1.12
s
0.138 1.23 0.0035 1.79 0.994 1.00 36.4 180 0.12 1.14
Simulation of Antoniw et al. (1990) 5.4e5 0.176 4.2e-7 0.667 0.18 1.00 0.012 120 7.3e-5 0.21
Simulation of Wallace et al. (1994) 0.041 71.1 64.6 606 0.998 1.00 5900 40000 0.025 2.18
Simulation of Bosslet et al. (1992) 0.15 4.47 7.88 0.464 1.00 1.00 1770 390 0.22 11.3
aIndices shown are spatial averages, for time = 30 min post prodrug injection (which was 72 h after ECA injection), except where otherwise noted.
Tumour -plasma concentration ratio, average concentration, spatial uniformity index, area under the curve and therapeutic index are reported. The
therapeutic index ofthe drug(ratio ofAUCin tumour vsAUC in plasma) is an importantoverall measure oftheeffectiveness/specificity ofan ECA-
prodrug therapy. bAUC and TI based on exponential extrapolation after first 3 h, to estimate the total exposure. cModel parameters for IgG were
similar to baseline, with the following changes: double Ka, one-halfAg7, 0l =0.46,Al
=0.0117 minm', A2 =0.000135 min-' (for B72.3) (Shockley et al.,
1992); D = 1.39 x 10-8 cm2 s-'(Clauss and Jain, 1990); P= 5.73 x 10- cm s-1 (Baxter and Jain, 1989; Gerlowski and Jain, 1986).
Case
0Glucuronidase-fusion protein - doxorubicin Bosslet et al.
(1994) developed a novel fusion protein with a humanised
carcinoembryonic antigen-specific variable region and the
enzymatic activity similar to that of human ,B-glucuronidase.
This ECA was used to convert a non-toxic glucuronide-
spacer derivative of doxorubicin. The prodrug was injected
(i.v. 250 mg kg-') 7 days after the i.v. injection of fusion
protein (20 mg kg-1). The baseline model parameters were
used with the exception of a lower Vmax=0.635
nmol min- x ,g (converted to 159 min-1); KM=1.3mM
(Bosslet et al., 1994); Cp°= 1.44 x 10-6 M; ECA al =0.68,
a2=0.32, Al =0.0283 min- , A2=0.00161 min-'; prodrug
ox1=0.99956, (2=-0.00044, Al=-0.076 min- , ).2=0.00064
min-'; drug oal=0.999, C2=0.0001, Al =0.48 min-',
A2=0.00167 min-1 (fit from pharmacokinetic data). In
addition, a lower antibody-binding affinity of 1.OX108M-1
and an antigen concentration of 3.0x 10-8 M were used to
better fit the in vivo ECA concentration profiles, with a
permeability coefficient of 3 x 10-7 cm S-' (3-fold lower than
lasma
imour
Time (min)
Time (min)
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baseline) and a partition coefficient fit as 0.17 (Figure 6a).
Bosslet et al. (1992) measured Ka in vitro to be 1.0 x 101 M-1
for the fusion protein, which is used in the model predicts a
much higher concentration 7 days after injection. Figure 6b
shows the prodrug and drug concentrations compared with
the model simulations. An 80-fold lower permeability
coefficient and a partition coefficient of 0.33 were required
for the prodrug, and a 20-fold higher Vmax (3180 min-'), in
order to match the experimental data. The drug permeability
was unchanged and its partition coefficient was 1.0. The
reduced apparent prodrug permeability is indicative of a high
degree of plasma protein binding, and/or a strongly flow-
limited uptake. The effect of these adjusted parameters may
be summarised as follows: the low Ag° and permeability are
implied by the low tumour ECA concentrations at early time
points (lest the model concentrations of the bound or free
ECA become higher than measured); the low Ka and low
partition coefficient are implied by the decreased tumour
concentration at later time points (if Ka or y were higher, the
bound and free ECA concentrations respectively, would be
too high at 7 days after injection); the low prodrug
permeability is required owing to the low tumour prodrug
concentrations at 30-60 min; the low prodrug partition
coefficient serves to reduce the prodrug concentration at 4
and 8 h; and the higher prodrug conversion rate (Wmax) is
needed to produce the measured tumour drug concentrations
for these ECA and prodrug concentrations.
Cytosine deaminase-L6 - 5-fluorouracil Wallace et al.
(1994) used an anti-idiotypic antibody that could bind to,
and help remove, circulating ECA for a cytosine deaminase
enzyme-L6 monoclonal antibody conjugate for converting 5-
FC to 5-FU. Nude mice bearing H2981 lung adenocarcinoma
were used. The use of the clearing antibody (13B) to remove
ECA from outside the tumour gave excellent tumour-plasma
ratios for 5-FU. The baseline model parameters were used
with the exception of Vmax= 3000 min-' and KM=2.5 mM
[arbitrary estimates, values not given by Wallace et al.
(1994)]; the same pharmacokinetic parameters and reduced
small molecule permeability were used as above in the fusion
protein simulations. The use of a third step, the clearing of
the ECA from the blood, would be very difficult to determine
without a good whole body pharmacokinetic model. There-
fore to allow comparision we used the experimental value of
ECA plasma concentration 24 h after injection of
200 jig (i.p.) 13B, which was 24 h after injection of
Figure 6 Comparison with Glu-Dox system of Bosslet et al.
(1994). (a) ECA concentration in the plasma (model, dot-dash
lime; data, *) tumour (model, solid line; data, 0) up to 7 days
after i.v. injection of 20mgkg- 1 fusion protein. (b) Prodrug:
(plasma model, solid line; plasma data, 0; tumour model, dashed
line; tumour data, >) and drug (tumour model, solid line; tumour
data, Cl) concentrations up to 8 hours after i.v. injection of
250mgkg-' prodrug.
Time (min)
Figure 7 Comparison with CD-L6-5FU system of Wallace et
al. (1994). Prodrug (plasma model, dashed line; plasma data, *;
tumour model, dashed line; tumour data,) and drug (plasma
model, dot-dash line; plasma data, 0; tumour model, dotted line;
tumour data, *) concentrations up to 90min after i.v. injection
of 800mgkg-' 5-FC prodrug.Microscopic model for ECA-prodrug therapy
M LT Baxter and RK Jain
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300 ,ug (i.v.) L6-CD ECA, and assumed that the concentra-
tion in normal tissues was reduced by an equivalent amount
(approximtely 41 times lower). Figure 7 shows a comparison
between the simulations and the data. The prodrug
concentrations were given only at one time point (30 min)
in the two-step approach. A partition coefficient of 0.17 for
the drug was found to give a good agreement between theory
and experiment for the drug plasma concentration.
Summary
The present model and simulations have served two purposes:
(i) a comparison of the perivascular distribution of active
agents for the BFA and ECA two-step approaches shows
much more uniform drug concentrations in the ECA
approach, with higher absolute concentration levels achiev-
able; (ii) a comparison of the model results averaged spatially
with data for a variety of experimental systems highlights the
importance of minimising the ECA concentration external to
the tumour. In particular the effective use of a clearing
antibody, as in Wallace et al. (1994) gives a dramatically
higher tumour-plasma ratio and therapeutic index. In
practice, residual amounts of ECA in normal tissues that
may escape a clearing antibody and convert prodrug and/or
return to the bloodstream, may be a limiting factor. A
strategy combining an enzyme with low Vmax and a 1 week
time delay between ECA and prodrug injections was also
seen to produce a good therapeutic ratio (Bosslet et al.,
1994), by minimising prodrug conversion outside of the
tumour. The ECA approach was found to have a higher and
more uniform concentration than the hapten with BFA, with
greater specificity as well. One potential disadvantage with
the ECA system compared with the use of radionuclides is
the difficulty of targeting cells distant from a patent blood
vessel; drug-resistant cells may be a problem for some
prodrugs, although the use of prodrugs of aklylating agents
may alleviate multidrug-resistant cells (Springer et al., 1994).
In addition, ECA with prodrug is also not used for cancer
detection. Exact quantitative agreement between these
simulations and experimental data has been hindered by the
assumption of homogeneous transport properties throughout
all regions of a tumour and by the simplified plasma
pharmacokinetic model (and transcapillary exchange) used,
as has been addressed elsewhere (Jain and Baxter, 1988;
Baxter and Jain, 1989; Strand et al., 1993; Baxter et al., 1994,
1995). It is hoped that this model will help to improve the
effectiveness of cancer therapies based on ECA-prodrug
systems.
Abbreviations
BA, benzoic acid mustard; BFA, bifunctional antibody; CEA,
carcinoembryonic antigen; CG2, carboxypeptidase; Dox, doxor-
ubicin; ECA, enzyme-conjugated antibody; Glu, glucuronidase;
MAb, monoclonal antibody; TAA, tumour associated antigen; 5-
FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; %i.d. g-1, percentage
of injected dose per gram in an organ or tissue.
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Appendix A Nomenclature
Ag0 Ag (t=0)= total (initial) concentration of binding sites in the extravascular space
CA Interstitial concentration of free (unbound) ECA (M)
Cp Interstitial concentration of prodrug (M)
CD Interstitial concentration of drug (M)
CB Interstitial concentration of bound ECA (M)Microscopic model for ECA-prodrug therapy
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Cii Concentration of the free species above [i=A (ECA), P (prodrug) or D (drug) (M)] wherej 1,2,3 represents the plasma,
well-perfused and poorly perfused peripheral compartments respectively
<C> Interstitial concentration averaged over the Krogh cylinder (M)
Di Interstitial diffusion coefficient for the mobile species (i=A,P,D) (cm2s-)
ke Elimination (metabolism) rate constant for ECA bound to TAA, s- 1
kf,kr Forward and reverse binding rate constants for ECA-TAA, M-1s-1 and s' respectively
Kjk,i Transfer coefficient of species i from compartment j to k for plasma pharmacokinetics
Ka Binding affinity for ECA-TAA (=kf/kr)
L One-half of mean intercapillary distance (also radius of Krogh cylinder), (gm)
Pi Effective vascular permeability coefficient for the mobile species (i=A,P,D), (cm s )
r Radial position (distance from centre of blood vessel) (gm)
S/V Surface area per unit volume for transcapillary exchange (cm-l)
t Time (min)
Vmax,KM Michaelis-Menten kinetic constants, minm and M-1 respectively. Vmax here is defined per unit enzyme concentration (and
may be converted from other units, e.g. nmol substrate per jig protein; if given as jumol substrate per unit enzyme activity, the
'concentration' of enzyme must also be given in terms of unit activity, or an arbitrary proportionality constant used); KM is also
the prodrug concentration at which V= Vmax/2
x,i)i Pharmacokinetic constants for free species in plasma (i=A,P,D) (Ai in min 1)
Yi Partition coefficient between interstitial and vascular space, = 1 unless otherwise indicated
p Blood vessel radius (gm)
T Time interval between the ECA and prodrug injections, (h)